Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.



In This Section

Home / Blurb / Discussion List

FDA Approves Pembrolizumab for Hepatocellular Carcinoma

Nov 12, 2018, 09:36 AM
On November 9, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc.) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Read the Merck press release here.

Posted 11/12/2018

Leave a comment